Molecular Laboratory Tests for the Diagnosis of Respiratory Tract Infection Due to Staphylococcus aureus
|
|
- Job Sanders
- 6 years ago
- Views:
Transcription
1 SUPPLEMENT ARTICLE Molecular Laboratory Tests for the Diagnosis of Respiratory Tract Infection Due to Staphylococcus aureus Lance R. Peterson Department of Pathology and Laboratory Medicine, NorthShore University HealthSystem (NorthShore) and University of Chicago, Evanston, Illinois When Staphylococcus aureus is the cause of ventilator-associated pneumonia or a bacterial infection following influenza, the infections are devastating if not treated promptly. Disease due to methicillin-resistant S. aureus (MRSA) continues to be of concern throughout most of the United States. Currently, the U.S. Food and Drug Administration (FDA) has cleared polymerase chain reaction tests for detection of MRSA in nasal swab specimens; however, there are no FDA-cleared tests for identifying S. aureus in purulent respiratory secretions. The real-time polymerase chain reaction tests for S. aureus (primarily MRSA) in nares provide results in,2 h and have sensitivities ranging from 95% to 100%, with specificities of 96% 99%; these results are comparable to that of standard cultures, which can take up to 3 4 days for final results. The FDA is encouraged to work closely with industry providers to expedite the evaluation and clearance process for molecular diagnostic devices detecting S. aureus (including MRSA) in the diagnosis of respiratory tract infection. The global plague of antibiotic-resistant infections is recognized as a serious threat to health care worldwide [1]. This threat is accompanied by a steady decrease in the research and development of new antimicrobial agents. One of the key pathogens is methicillin-resistant Staphylococcus aureus (MRSA) [1], which can cause a destructive necrotizing pneumonia with high mortality [2]. We need accurate and fast laboratory detection of infection. Unfortunately, until very recently, there was virtually no federal funding for research into the diagnosis and treatment of bacterial infectious diseases [3]. The purpose of this review is to (1) discuss the role of S. aureus (including MRSA) in pneumonia; (2) review the promise and reality of molecular diagnostic testing for respiratory tract infection (RTI); (3) summarize the Correspondence: Lance R. Peterson, MD, NorthShore University HealthSystem, Dept of Pathology and Laboratory Medicine, 2650 Ridge Ave, Walgreen Bldg, SB525, Evanston, IL (lance1@uchicago.edu). Clinical Infectious Diseases 2011;52(S4):S361 S366 Ó The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please journals.permissions@oup.com /2011/52S4-0013$14.00 DOI: /cid/cir052 currently available molecular technology based on the published literature; and (4) describe broad interventions that can reduce the likelihood of MRSA as a potential pathogen in RTI. STAPHYLOCOCCUS AUREUS AS A PATHOGEN IN PNEUMONIA Many cases of hospital-acquired pneumonia are due to Pseudomonas aeruginosa, Acinetobacter species, and S. aureus [2]; S. aureus is the number one cause of ventilator-associated pneumonia, accounting for 24.4% of cases [4]. In U.S. hospitals, 50% of S. aureus infections involve MRSA. The estimated number of MRSA-related hospitalizations more than doubled between 1999 and 2005 [5]. Of note, there has been some apparent success in the reduction of invasive infection across the United States since 2005, but most of the improvement was related to bloodstream infection [6], which may be tied to improvement in the care of central venous catheters. The lack of a reduction in the rate of MRSA disease associated with documented improvement in hand hygiene performance suggests any reduction in national MRSA invasive infection is more Molecular Tests For Staphylococcal RTI d CID 2011:52 (Suppl 4) d S361
2 complex than a general improvement in basic infection control practice [7]. Additionally, Delorme et al [8] recently reported a 183% increase in MRSA infections among long-term care facility residents during the period , with an overall increase in disease among inpatients and outpatients of 77% a disease rate.100-fold higher than the U.S. national rate of tuberculosis [9]. In fact, by 2005, MRSA was causing greater mortality in the United States than were tuberculosis, Salmonella infection, influenza, and human immunodeficiency virus AIDS combined [10]. Clearly, now is the time for research into better understanding the effective detection and control strategies to deal with MRSA, perhaps particularly for RTI. Importantly, MRSA-associated ventilator-associated pneumonia likely has a higher mortality rate than does that due to methicillin-susceptible S. aureus (MSSA). The difference is largely due to inadequate initial therapy [11]. In developed countries, the incidence of community-acquired pneumonia (CAP) in adults is estimated to range from 5 to 11 cases per 1000 persons per year, with 20% of patients requiring hospital admission [12]. S. aureus is not a common etiology of CAP, with a reported incidence of 1% 5% of CAP cases [12]. The incidence is likely substantively higher during outbreaks of influenza. Community-associated MRSA pneumonia may be an emerging infection, with 15 and 10 cases reported to (CDC) in the and influenza seasons, respectively [12]. The recent 2009 pandemic influenza A (H1N1) season highlighted the potential problem of S. aureus as a cause of pneumonia [13]. As seen in Figure 1, influenza can be a significant illness during a substantial part of the year, and the season was marked by pandemic novel influenza virus [14]. During the period from May through August 2009, there were 77 postmortem lung specimens examined from the United States. Bacteria were detected using a broad-range polymerase chain reaction (PCR) assay targeting 16S ribosomal DNA gene in extracted tissue samples. Concurrent bacterial infection was found in 29% of the 77 cases. Of the bacterial infections detected, 10 were caused by Streptococcus pneumoniae, 7 by S. aureus (one should assume at least some were MRSA), 2 by Streptococcus mitis, and 1 by Haemophilus influenza; 4 cases involved multiple pathogens [13]. Thus, although S. aureus (including MRSA) is not highly prevalent as a cause of outpatient pneumonia, it can become an important cause of morbidity and mortality in both the inpatient and community settings. POTENTIAL FOR THE RAPID DIAGNOSIS OF PNEUMONIA One of the historic and potentially reliable tests for rapid diagnosis is the Gram stain. Sputum Gram stains were prospectively evaluated in 1390 patients with CAP who were hospitalized during the period of January 2002 through June Of the 1390 patients, 12.8% fulfilled the criteria for study inclusion (ie, a high-quality sputum sample was available and the same pathogen was recovered from both blood and sputum cultures). The Gram stain results suggested the presence of Figure 1. Influenza trends for the United States showing the seasonal trend for the pandemic year [14]. CDC, Centers for Disease Control and Prevention; NREVSS, National Respiratory and Enteric Virus Surveillance System; WHO, World Health Organization. S362 d CID 2011:52 (Suppl 4) d Peterson
3 pneumococci in 82% of patients, staphylococci in 76%, and gram-negative bacteria in 79%. Specificity was very good, at 93% for pneumococci and 96% for both staphylococci and gram-negative bacteria [15]. The main limitation with Gram stain results is the absence of antimicrobial susceptibility test information that can guide therapy. Further development of molecular diagnostics will eventually make Gram stains obsolete, but for now they can be helpful. From the molecular viewpoint, a promising development is the recognition of a soluble triggering receptor (strem-1) on myeloid cells that can be measured in respiratory secretions [16]. strem-1 is expressed by neutrophils, macrophages, and mature monocytes. An initial report suggested that strem-1 levels can separate bacterial pneumonia from noninfectious causes of pulmonary inflammation. Measurement of strem-1 in 148 patients detected the presence of bacterial or fungal infection with a sensitivity of 98% and a specificity of 90% [16]. It is disappointing that a subsequent investigation did not confirm the original observations [17]. The second study prospectively evaluated 105 adult patients undergoing mechanical ventilation who underwent bronchoalveolar lavage (BAL). The diagnostic sensitivity of strem-1 was 42.1% with a specificity of 75.6% [17]. The study included 19 patients that were classified as having definite ventilator-associated pneumonia, which was defined as a positive quantitative BAL culture result. There were also 21 patients (20.0%) who clearly did not have infection [17]. The detection of host response protein(s) holds much promise for the future specific diagnosis of infectious diseases, but the field is still in its infancy, and additional research is needed to understand the precise human biological response to each unique infectious pathogen. REAL-TIME PCR FOR THE DIAGNOSIS OF PNEUMONIA Real-time PCR (rtpcr) has revolutionized the detection of pathogens by combining the PCR chemistry with probe detection of amplified products into a single technology that provides amplification and target detection in,2 h [18 20]. Amazingly, the 10-year anniversary of this technology was in Early application of rtpcr focused on detection of MRSA and, later, MSSA from nasal surveillance swabs. At least 3 instruments and their associated assays have been cleared by the U.S. Food and Drug Administration (FDA) for diagnostic use [21 23]. These elegant assays specifically detect S. aureus and distinguish those strains that are MRSA; with these tests, there is no concern with any interference from coagulase-negative staphylococci that may be present (typically as contaminants) in the respiratory samples. There is one full report of the use of this type of test, in a modified version, for the detection of S. aureus (MSSA and MRSA combined) and of MRSA in wound cultures [24]. However, no one has yet published data on the use of such tests for the specific diagnosis of pneumonia due to S. aureus or MRSA. One potential use of these new rtpcr tests is to determine the S. aureus colonization status of patients admitted with CAP and to then determine whether the colonization does, or does not, predict the potential for MRSA as the agent of the lower RTI. In a study of 5779 nasal rtpcr tests for MRSA, done within 24 h of a clinical culture for any type of infection, a positive nasal MRSA test result predicted a 12.9-fold increased likelihood of MRSA as a cause of the infectious disease [25]. Specifically for pneumonia, 5.6% of 402 respiratory cultures grew MRSA, with a relative risk equal to an 18.3-fold higher likelihood of MRSA causing the RTI when the patient was nasally colonized with MRSA [25]. However, on a cautionary note, 33% of MRSA infections occurred in patients who had a negative nasal MRSA test result. The overall sensitivity, specificity, and negative predictive value for using nasal colonization status to predict RTI with (or without) MRSA were 75%, 90%, and 98%, respectively [25]. Thus, although the knowledge of MRSA nasal colonization status is helpful in deciding whether someone may have a MRSA-associated pneumonia, the accuracy of prediction is far from sufficient. A multicenter, preclinical study was done to assess the utility of rtpcr using the Xpert MRSA/SA SSTI (Cepheid) test on 114 clinical wound swab specimens, with culture serving as the reference method. The results of that study are shown in Table 1 [24]. As can be seen from the results, although the overall ability to detect of S. aureus was excellent, there was some erroneous determination as to whether the S. aureus was MRSA or MSSA, which could lead to some very major treatment errors (eg, treatment of MRSA with a b-lactam) unless all samples are cultured with susceptibility tests performed. Also, all the available rtpcr tests only detect S. aureus and MRSA, so if any other potential pathogens are suspected, full culture and sensitivity testing are necessary. Two other studies performed by a single research group assessed both wound cultures and respiratory specimens. They investigated the preclinical BD GeneOhm combined StaphSR assay, which is an rtpcr test for detection of S. aureus (MSSA BD GeneOhm) or MRSA (MRSA BD GeneOhm) and compared it with an in-house assay for MSSA (NorthShore-developed MSSA) and the FDA-cleared BD GeneOhm MRSA Assay for Table 1. Results of a Multicenter Xpert MRSA/SA SSTI (Cepheid) Trial on Clinical Wound Swabs Testing for Staphylococcus aureus and MRSA Organism Sensitivity, % (n/n) Specificity, % (n/n) NPV, % (n/n) MSSA and MRSA 100 (55/55) 96.6 (57/59) 100 (57/57) MRSA 97.1 (34/35) 96.2 (76/79) 98.7 (76/77) NOTE. Data are from [24]. MSSA, methicillin-susceptible S. aureus; NPV, negative predictive value. Molecular Tests For Staphylococcal RTI d CID 2011:52 (Suppl 4) d S363
4 nasal colonization on 200 clinical samples. The results are shown in Table 2. MSSA was found in 49 specimens by culture, and MRSA was found in 40 samples [26 27]. With regard to the 3 false-positive MSSA rtpcr results, all subjects were receiving anti-staphylococcal therapy at the time of testing, and for 2 patients, cultures of samples from the same body site subsequently grew MSSA. There were 4 false-negative MSSA rtpcr results, 3 of which involved mixed bacterial growth, with rare to few S. aureus isolates in the culture. Of the 2 false positive MRSA rtpcr results, no explanation could be found for the false positive result. There were also 3 false-negative MRSA rtpcr results, 2 could not be explained. Of the 34 respiratory samples in this study, 2 grew MRSA and 4 grew S. aureus (MSSA); all were correctly identified by the molecular diagnostic tests when compared with the diagnostic laboratory culture. Interestingly, one of the false-negative MRSA rtpcr test results was from a sputum sample that had been initially reported as mixed flora by the clinical laboratory, and MRSA was only detected as part of the research study [26 27], suggesting the sensitivity of the new rtpcr assays is very close to that of routine culture. Finally, one other report used the FD- cleared BD GeneOhm MRSA Assay for nasal colonization to analyze 196 sputum specimens obtained from 156 patients for MRSA [28]. These authors used a less robust extraction method and found that the rtpcr test had a sensitivity and specificity of 97% and 92%, respectively, for 32 culture-positive samples [28]. Of the 12 falsepositive rtpcr test results in this study, 10 involved patients who had an MRSA-positive clinical or surveillance culture within 2 weeks of the rtpcr assay. Nine samples (5%) remained unresolved after repeated testing and therefore could not provide a result; this was most likely because a relatively simple extraction method was used for processing a complex sample, such as sputum [28]. All of the clinical samples in these studies were purulent material for which the physician suspected infection. The rtpcr tests performed adequately but not as well as culture for determining the presence of S. aureus and distinguishing which strains were MRSA. Although these tests may not be quite ready for clinical application in the detection of MSSA and MRSA as a cause of pneumonia, there is reason for optimism that, with very little effort, both the Cepheid and BD-GeneOhm assays could be clinically useful for the detection of S. aureus in RTI specimens and could provide immediate determination of methicillin susceptibility. Such information would be very useful in helping to avoid the unnecessary use of antimicrobial agents targeted against MSSA or MRSA in the initial empirical therapy for pneumonia. ELIMINATING MRSA AS A POTENTIAL PATHOGEN Reports continue that MRSA is a pathogen of increasing importance. As noted earlier, Delorme et al [8] assessed the problem of staphylococcal disease in Northeastern Ohio during They found that 59% of the 1612 S. aureus isolates were MRSA and that the burden of disease was 589 infections per 100,000 inhabitants; there was an overall increase in staphylococcal infection of 77% between the 2 years [8]. Furthermore, they observed an increase in the rate of S. aureus disease for all age groups, with a 58% increase among outpatients and a 43% increase among inpatients. In this population, 66% of infected persons had no risk factors [8]. The burden of disease in 2005 was.100-fold that of tuberculosis in the United States [9]. Thus, effective diagnosis of MRSA in any disease syndrome with potentially serious consequences, such as pneumonia, is critical. Another approach for reducing the risk of MRSA pneumonia is to eliminate the possibility of MRSA as a cause of any disease by universal screening, contact isolation, and decolonization. One 3-hospital health care organization deploying this method found that the MRSA disease rate decreased by.60% in 1 year [29], and they concomitantly found it cost-effective [30]. The Veterans Administration (VA) health care system of 153 hospitals reported on their first 21 months of universal screening with contact isolation of MRSA-positive patients, encompassing 1,213,646 admissions covering 5,296,757 patient-days of care. The VA recorded a 24% reduction in the rate of MRSA disease throughout the system for the patients who were not treated in the intensive care unit (ICU; P 5.04) and a 77% reduction for ICU patients (P,.001) after 21 months [31]. Relevant to this review on using molecular testing for staphylococcal Table 2. Results of a Single-Center Study of the BD GeneOhm Realt-Time Polymerase Chain Reaction Test for Methicillin-Susceptible Staphylococcus aureus (MSSA) and Methicillin-Resistant S. aureus (MRSA), Compared with a US Food and Drug Administration Cleared Test for Nasal MRSA Surveillance (BD GeneOhm) and an In-House Test for MSSA (NorthShore) on 200 Clinical Samples Test Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI) MSSA BD GeneOhm 96 (89 99) 97 (92 99) 97 (90 99) 96 (91 99) NorthShore Developed MSSA 94 (87 98) 99 (95 100) 99 (94 100) 96 (90 99) MRSA BD GeneOhm 95 (83 99) 99 (96 100) 95 (83 99) 99 (96 100) MRSA Nasal 98 (87 100) 98 (94 99) 91 (78 97) 99 (97 100) NOTE. Clinical samples included 123 wound samples, 34 respiratory specimens, 20 tissue specimens, 16 body fluid specimens, 2 catheter samples, and 5 other samples [26 27]. CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value. S364 d CID 2011:52 (Suppl 4) d Peterson
5 pneumonia, the rate of ventilator-associated pneumonia due to MRSA decreased 53% while the ventilator use rate decreased 19.7% (P,.001); non ventilator-associated pneumonia due to MRSA associated with hospitalization also was reduced by 67% in the VA program [31]. However, the search and destroy intervention for MRSA (widespread surveillance and contact isolation with or without decolonization) remains controversial [32]. If the goal is to reduce MRSA-associated respiratory tract disease, it may be necessary to adopt the search and destroy as a national policy, as is in effect in the Netherlands [33]. SUMMARY AND CONCLUSIONS Molecular diagnostics are redefining how we manage infectious diseases, and this trend will accelerate. Same-day (ie, in,4 h) diagnostics are here for many viral and bacterial tests. Unfortunately, at the present time, the only rapid molecular diagnostic tests for use in pneumonia are those for tuberculosis and viral respiratory infection; many lack sufficient sensitivity, and the viral diagnostic tests do not discriminate between infection and colonization [34 35]. Point-of-care molecular tests, planned for the near future, will further speed diagnostic information available to physicians who are treating an infectious disease [36]. This will place the experts in test interpretation and therapy at the heart of clinical management. Developing a reliable test for detection of S. aureus and MRSA as a cause of pneumonia remains a challenge [37], but it is not insurmountable. The current technical challenges for RTIs are (1) developing simple and robust specimen-processing procedure(s) before PCR testing; (2) modestly enhancing the sensitivity and specificity of the S. aureus and MRSA tests already available for clinical infection diagnosis; and (3) multiplexing the tests for the relatively few major pathogens (bacterial and viral) specifically associated with unique disease syndromes, such as CAP, hospital-acquired pneumonia, and ventilatorassociated pneumonia. Rapid tests for the specific detection of S. aureus and MRSA in respiratory secretions are very close to being clinically useful. The US FDA should be encouraged to work closely with the appropriate industry providers so as to bring these tests into clinical use as soon as can be reasonably done. The tests can be of great help to the practicing physician in the accurate detection of staphylococcal RTI. The deployment of these molecular diagnostic tests can lower patient morbidity and mortality, as well as limit the use of antimicrobials directed against (susceptible) S. aureus or MRSA to those patients who are really need treatment for S. aureus infection. Acknowledgments Supplement sponsorship. This article was published as part of a supplement entitled Workshop on Molecular Diagnostics for Respiratory Tract Infections. The Food and Drug Administration and the Infectious Diseases Society of America sponsored the workshop. AstraZeneca Pharmaceuticals, Bio Merieux, Inc., Cepheid, Gilead Sciences, Intelligent MDX, Inc., Inverness Medical Innovations, and Roche Molecular Systems provided financial support solely for the purpose of publishing the supplement. Potential conflicts of interest. L. R. P. has received research funding from Wyeth Pharmaceuticals, Cepheid, NorthShore, BD GeneOhm, GSK, Johnson & Johnson, Merck, MicroPhage, Nanogen, Nanosphere, Roche, 3M, and the Washington Square Health Foundation; has served as a consultant for research projects to Cepheid, BD GeneOhm, Roche, 3M, and Wyeth Pharmaceuticals; and has spoken at supported programs for Wyeth Pharmaceuticals, Cepheid, BD GeneOhm, and Roche. References 1. Spellberg B, Guidos R, Gilbert D Bradley J, et al. Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: Niederman MS, Craven DE, Bonten MJ, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: Rice LB. Progress and challenges in implementing research to combat ESKAPE pathogens. In: Program and abstracts, Fifth Decennial International Conference on Healthcare-Associated Infections Atlanta, GA: Paper Hidron AI, Edwards JR, Patel J, et al. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, Infect Control Hosp Epidemiol 2008; 29: Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, Emerg Infect Dis 2007; 13: Kallen AJ, Mu Y, Bulens S, et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators of the Emerging Infections Program. Health care-associated invasive MRSA infections, JAMA 2010; 304: Mertz D, Dafoe N, Walter SD, et al. Effect of a multifaceted intervention on adherence to hand hygiene among healthcare workers: a clusterrandomized trial. Infect Control Hosp Epidemiol 2010; 31: Delorme T, Rose S, Senita J, Callahan C, Nasr P. Epidemiology and susceptibilities of methicillin-resistant Staphylococcus aureus in Northeastern Ohio. Am J Clin Pathol 2009; 132: Pratt R, Robison V, Navin T, Menzies H. Trends in tuberculosis United States, MHWR Morb and Mortal Wkly Rep 2008; 57: Available at: mm5711a2.htm. Accessed 30 March DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009; 119: Athanassa Z, Siempos I, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31: Ho PL, Cheng VC, Chu CM. Antibiotic resistance in communityacquired pneumonia caused by Streptococcus pneumoniae, methicillinresistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 2009; 136: Louie J, Jean C, Chen T-H, et al. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) United States, May August Morb Mortal Wkly Rep 2009; 58: Centers for Disease Control and Prevention. FluView: Influenza Season Week 11 ending March 20, Available at: Accessed 29 March Molecular Tests For Staphylococcal RTI d CID 2011:52 (Suppl 4) d S365
6 15. Anevlavis S, Petroglou N, Tzavaras A, et al. A prospective study of the diagnostic utility of sputum Gram stain in pneumonia. J Infect 2009; 59: Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: Anand NJ, Zuick S, Klesney-Tait J, Kollef MH. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. Chest 2009; 135: Ince J, McNally A. Development of rapid, automated diagnostics for infectious disease: advances and challenges. Expert Rev Med Devices 2009; 6: Ishmael FT, Stellato C. Principles and applications of polymerase chain reaction: basic science for the practicing physician. Ann Allergy Asthma Immunol 2008; 101: Kubista M, Andrade JM, Bengtsson M, et al. The real-time polymerase chain reaction. Mol Aspects Med 2006; 27: Paule SM, Hacek DM, Kufner B, et al. Performance of the BD GeneOhm methicillin-resistant Staphylococcus aureus test before and during high-volume clinical use. J Clin Microbiol 2007; 45: Wolk DM, Picton E, Johnson D, et al. Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares. J Clin Microbiol 2009; 47: Peterson LR, Liesenfeld O, Woods CW, et al. Multicenter evaluation of the LightCycler(R) MRSA advanced test as a rapid method for detection of methicillin-resistant Staphylococcus aureus (MRSA) in nasal surveillance swabs. J Clin Microbiol [Epub ahead of print]. 24. Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009; 47: Robicsek A, Suseno M, Beaumont JL, Thomson RB Jr., Peterson LR. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol 2008; 46: McClure JT, Kamdar MA, Paule SM, Truchon K, Peterson LR. Realtime PCR tests performances for direct detection of Staphylococcus aureus and MRSA on clinical samples. In: Program, and abstracts. 106th General Meeting of the American Society for Microbiology. Orlando, Florida: May 21 25, Abstract C McClure JT, Mehta M, Paule SM, Mangold K, Truchon K, Peterson LR. Performance of an investigational commercial real-time PCR assay for direct detection of Staphylococcus aureus and MRSA on clinical samples. In: Program and abstracts. Forty-fourth Annual Meeting, Infectious Diseases Society of America. Toronto, Canada: October 12 15, Abstract Ohl CA, Varela V, White M, Palavecino EL, Karchmer TB. Performance of a real-time PCR assay for the detection of methicillinresistant S. aureus (MRSA) in sputum specimens. In: Program and abstracts. Forty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: September 27 30, Abstract D Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148: Peterson LR, Hacek DM, Robicsek A. 5 Million Lives Campaign. Case study: an MRSA intervention at Evanston Northwestern Healthcare. Jt Comm J Qual Patient Saf 2007; 33: Evans ME, Jain R, Roselle GA, Kralovic SM, Ambrose M, Simbartl LA, Obrosky Ds, Freyberg RW. Results of a Veterans Affairs initiative to prevent healthcare-associated methicillin-resistant Staphylococcus aureus infections. In: Program and abstracts. Fifth Decennial International Conference on Healthcare-Associated Infections Atlanta, GA: March 18 22, Paper Peterson LR, Diekema DJ. To screen or not to screen for methicillinresistant Staphylococcus aureus. J Clin Microbiol 2010; 48: Vos MC, Behrendt MD, Melles DC, et al. 5 Years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol 2009; 30: Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression. PLoS One 2008; 3:e Wu W, Tang Y-W. Emerging molecular assays for detection and characterization of respiratory viruses. Clin Lab Med 2009; 29: Holland CA, Kiechle FL. Point-of-care molecular diagnostic systems past, present and future. Curr Opin Microbiol 2005; 8: Persing D. Sputum, the final frontier: PCR from the research bench to the MRSA diagnostic trench. Med Lab Obs 2008; 40: S366 d CID 2011:52 (Suppl 4) d Peterson
Success for a MRSA Reduction Program: Role of Surveillance and Testing
Success for a MRSA Reduction Program: Role of Surveillance and Testing Singapore July 13, 2009 Lance R. Peterson, MD Director of Microbiology and Infectious Disease Research Associate Epidemiologist, NorthShore
More informationFM - Male, 38YO. MRSA nasal swab (+) Due to positive MRSA nasal swab test, patient will be continued on Vancomycin 1500mg IV q12 for MRSA treatment...
Jillian O Keefe Doctor of Pharmacy Candidate 2016 September 15, 2015 FM - Male, 38YO HPI: Previously healthy male presents to ED febrile (102F) and in moderate distress ~2 weeks after getting a tattoo
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationCME/SAM. Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting
Microbiology and Infectious Disease / Xpert MRSA/SA in Pediatric Blood Cultures Validation and Implementation of the GeneXpert MRSA/SA Blood Culture Assay in a Pediatric Setting David H. Spencer, MD, PhD,
More informationIDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA
page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationEvaluation of Multiple Real-Time PCR Tests on Nasal Samples in a Large MRSA Surveillance Program
Evaluation of Multiple Real-Time PCR Tests on Nasal Samples in a Large MRSA Surveillance Program Parul A. Patel, MLS(ASCP), CCRP, 1 Ari Robicsek, MD, 1,2 Althea Grayes, MLS(ASCP), 1 Donna M. Schora, MLS(ASCP),
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Activity C: ELC Prevention Collaboratives John Jernigan, MD, MS Alex Kallen, MD, MPH Division of Healthcare Quality Promotion Centers for Disease
More informationHorizontal vs Vertical Infection Control Strategies
GUIDE TO INFECTION CONTROL IN THE HOSPITAL Chapter 14 Horizontal vs Vertical Infection Control Strategies Author Salma Abbas, MBBS Michael Stevens, MD, MPH Chapter Editor Shaheen Mehtar, MBBS. FRC Path,
More informationActive Bacterial Core Surveillance Site and Epidemiologic Classification, United States, 2005a. Copyright restrictions may apply.
Impact of routine surgical ward and intensive care unit admission surveillance cultures on hospital-wide nosocomial methicillin-resistant Staphylococcus aureus infections in a university hospital: an interrupted
More informationSource: Portland State University Population Research Center (
Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:
More informationVaccination as a potential strategy to combat Antimicrobial Resistance in the elderly
Vaccination as a potential strategy to combat Antimicrobial Resistance in the elderly Wilbur Chen, MD, MS 22-23 March 2017 WHO meeting on Immunization of the Elderly The Problem Increasing consumption
More informationInfection Control Manual Residential Care Part 3 Infection Control Standards IC7: 0100 Methicillin Resistant Staphylococcus aureus
Infection Control Manual Residential Care Part 3 Infection Control Standards IC7: 0100 Methicillin Resistant Staphylococcus aureus IC7: 0100 MRSA 1. Purpose To outline the assessment, management, room
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationRapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management. Martin McHugh Clinical Scientist
Rapid molecular testing to detect Staphylococcus aureus in positive blood cultures improves patient management Martin McHugh Clinical Scientist 1 Staphylococcal Bacteraemia SAB is an important burden on
More informationCompliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings
Compliance with antibiotic treatment guidelines in managed care patients with communityacquired pneumonia in ambulatory settings Jasmanda H. Wu, Ph.D., 1 David H. Howard, Ph.D., 2 John E. McGowan, Jr.,
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationThe importance of infection control in the era of multi drug resistance
Dr. Kumar Consultant Infectious Diseases Physician Hospital Sungai buloh The importance of infection control in the era of multi drug resistance Nosocomial infections In Australian acute hospitals 200,000
More information3/1/2016. Antibiotics --When Less is More. Most Urgent Threats. Serious Threats
Antibiotics --When Less is More Ralph Gonzales, MD, MSPH Associate Dean, Clinical Innovation School of Medicine VP, Clinical Innovation, UCSF Health Most Urgent Threats Serious Threats Multidrug-Resistant
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationSurveillance of Multi-Drug Resistant Organisms
Surveillance of Multi-Drug Resistant Organisms Karen Hoffmann, RN, MS, CIC Associate Director Statewide Program for Infection Control and Epidemiology (SPICE) University of North Carolina School of Medicine
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationReportable Disease Surveillance & Antibiotic Resistant Bacteria
Reportable Disease Surveillance & Antibiotic Resistant Bacteria Kevin T. Kavanagh, MD, MS Health Watch USA December 16, 2015 This presentation is the express opinion of Kevin T. Kavanagh, MD, MS The Crisis
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationPhysician Rating: ( 23 Votes ) Rate This Article:
From Medscape Infectious Diseases Conquering Antibiotic Overuse An Expert Interview With the CDC Laura A. Stokowski, RN, MS Authors and Disclosures Posted: 11/30/2010 Physician Rating: ( 23 Votes ) Rate
More informationRisk Factors for Persistent MRSA Colonization in Children with Multiple Intensive Care Unit Admissions
University of Massachusetts Amherst From the SelectedWorks of Nicholas G Reich July, 2013 Risk Factors for Persistent MRSA Colonization in Children with Multiple Intensive Care Unit Admissions Victor O.
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationDr Nata Menabde Executive Director World Health Organization Office at the United Nations Global action plan on antimicrobial resistance
Global action plan on antimicrobial resistance Dr Nata Menabde Executive Director World Health Organization Office at the United Nations Proportion of MDR among previously treated TB cases, 1994-2010 0-
More informationNew Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs
New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs Patrick R. Murray, PhD Senior Director, WW Scientific Affairs 2017 BD. BD, the BD Logo and all other trademarks
More informationOther Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 50: Other Enterobacteriaceae Author Kalisvar Marimuthu, MD Chapter Editor Michelle Doll, MD, MPH Topic Outline Topic outline - Key Issues Known
More informationAntimicrobial stewardship
Antimicrobial stewardship Magali Dodemont, Pharm. with the support of Wallonie-Bruxelles International WHY IMPLEMENT ANTIMICROBIAL STEWARDSHIP IN HOSPITALS? Optimization of antimicrobial use To limit the
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More informationMethicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus By Karla Givens Means of Transmission and Usual Reservoirs Staphylococcus aureus is part of normal flora and can be found on the skin and in the noses of one
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationMDRO in LTCF: Forming Networks to Control the Problem
MDRO in LTCF: Forming Networks to Control the Problem Suzanne F. Bradley, M.D. Professor of Internal Medicine Division of Infectious Disease University of Michigan Medical School VA Ann Arbor Healthcare
More informationComments from The Pew Charitable Trusts re: Consultation on a draft global action plan to address antimicrobial resistance September 1, 2014
Comments from The Pew Charitable Trusts re: Consultation on a draft global action plan to address antimicrobial resistance September 1, 2014 The Pew Charitable Trusts is an independent, nonprofit organization
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationLecture Notes: The Importance of Nurse Empowerment. Theme: It is not the Nurses Fault
Lecture Notes: The Importance of Nurse Empowerment. Theme: It is not the Nurses Fault Kentucky Nurses Association, Nov. 2, 2018 Kevin T. Kavanagh, MD, MS Health Watch USA sm Slide 1: Thank you very much,
More informationASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies
ASCENSION TEXAS Antimicrobial Stewardship: Practical Implementation Strategies Theresa Jaso, PharmD, BCPS (AQ-ID) Network Clinical Pharmacy Specialist Infectious Diseases Seton Healthcare Family Ascension
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationPrevalence & Risk Factors For MRSA. For Vets
For Vets General Information Staphylococcus aureus is a Gram-positive, aerobic commensal bacterium of humans that is carried in the anterior nares of approximately 30% of the general population. It is
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationANTIBIOTICS IN THE ER:
ANTIBIOTICS IN THE ER: EXPLORING THE ROLE OF ANTIMICROBIAL STEWARDSHIP IN THE EMERGENCY DEPARTMENT ANGELINA DAVIS, PHARMD, MS, BCPS (AQ-ID) LIAISON CLINICAL PHARMACIST DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH
More informationHosted by Dr. Jon Otter, Guys & St. Thomas Hospital, King s College, London A Webber Training Teleclass 1
Andreas Voss, MD, PhD Professor of Infection Control Radboud University Nijmegen Medical Centre & Canisius-Wilhelmina Hospital Nijmegen, Netherlands Hosted by Dr. Jon O0er Guys & St. Thomas NHS Founda
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationCombating Antimicrobial Resistance: The Way Forward
Combating Antimicrobial Resistance: The Way Forward James M. Hughes, MD Professor of Medicine and Public Health Emory University Atlanta, GA NIAA Antibiotic Symposium November 14, 2014 Disclosure No conflicts
More informationImpact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital
Impact of Antimicrobial Resistance on Human Health Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital AMR in Foodchain Conference, UCD, Dec 2014 Sir Patrick Dun s Hospital
More informationChromogenic Media vs Real-Time PCR for Nasal Surveillance of Methicillin-Resistant Staphylococcus aureus
Microbiology and Infectious Disease / METHODS FOR MRSA DETECTION Chromogenic Media vs Real-Time PCR for Nasal Surveillance of Methicillin-Resistant Staphylococcus aureus Impact on Detection of MRSA-Positive
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationClinical utility of the Xpert MRSA assay for early detection of methicillin-resistant Staphylococcus aureus
MOLECULAR MEDICINE REPORTS 7: 11-15, 2013 Clinical utility of the Xpert MRSA assay for early detection of methicillin-resistant Staphylococcus aureus AE-CHIN OH 1, JIN KYUNG LEE 1,3, HA NA LEE 4, YOUNG
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationThe Use of Procalcitonin to Improve Antibiotic Stewardship
The Use of Procalcitonin to Improve Antibiotic Stewardship Disclosures I have no actual or potential conflict of interest in relation to this presentation. Patrick A. Laird, DNP, RN, ACNP-BC Objectives
More informationAntibiotic resistance: the rise of the superbugs
Antibiotic resistance: the rise of the superbugs Allen Cheng Associate Professor of Infectious Diseases Epidemiology, Alfred Health; Monash University About me Specialist in infectious diseases Head, Infection
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationCarbapenemase-Producing Enterobacteriaceae (CPE)
Carbapenemase-Producing Enterobacteriaceae (CPE) September 21, 2017 Maryam Khan Peel Public Health Madeleine Ashcroft Public Health Ontario Objectives Differentiate the acronyms related to CPE (CPE,CPO,CRE,CRO)
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationFinnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs
PathoProof TM Mastitis PCR Assay Mikko Koskinen, Ph.D. Director, Diagnostics, Finnzymes Oy Real time PCR based mastitis testing in milk monitoring programs PathoProof Mastitis PCR Assay Comparison of the
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationDr. P. P. Doke. M.D., D.N.B., Ph.D., FIPHA. Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune
Dr. P. P. Doke M.D., D.N.B., Ph.D., FIPHA Professor, Department of Community Medicine, Bharati Vidyapeeth Medical College, Pune 1 Anti microbial resistance is now a global geometrically increasing threat
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationInfection Control of Emerging Diseases
2016 EPS Training Event Martin E. Evans, MD Director, VHA MDRO Program National Infectious Diseases Service Lexington, KY & Cincinnati, OH Infection Control of Emerging Diseases 2016 EPS Training Event
More informationAntimicrobial Resistance. The Case for Diagnostics to Better Direct Therapy
Antimicrobial Resistance The Case for Diagnostics to Better Direct Therapy Objectives Explain the medical significance of antibiotic resistance Assess the medical impact of disease, such as pneumonia and
More informationImpact of a Standardized Protocol to Address Outbreak of Methicillin-resistant
Impact of a Standardized Protocol to Address Outbreak of Methicillin-resistant Staphylococcus Aureus Skin Infections at a large, urban County Jail System Earl J. Goldstein, MD* Gladys Hradecky, RN* Gary
More informationApproval Signature: Original signed by Dr. Michel Tetreault Date of Approval: July Review Date: July 2017
WRHA Infection Prevention and Control Program Operational Directives Admission Screening for Antibiotic Resistant Organisms (AROs): Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant
More informationEpidemiology of early-onset bloodstream infection and implications for treatment
Epidemiology of early-onset bloodstream infection and implications for treatment Richard S. Johannes, MD, MS Marlborough, Massachusetts Health care-associated infections: For over 35 years, infections
More informationCan we trust the Xpert?
Can we trust the Xpert? An evaluation of the Xpert MRSA/SA BC System and an assessment of potential clinical impact Dr Kessendri Reddy Division of Medical Microbiology, NHLS Tygerberg Fakulteit Geneeskunde
More informationInt.J.Curr.Microbiol.App.Sci (2016) 5(12):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 12 (2016) pp. 644-649 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.512.071
More informationAppropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationThe Impact of meca Gene Testing and Infectious Diseases Pharmacists. Intervention on the Time to Optimal Antimicrobial Therapy for ACCEPTED
JCM Accepts, published online ahead of print on 7 May 2008 J. Clin. Microbiol. doi:10.1128/jcm.00801-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationCHAPTER 1 INTRODUCTION
1 CHAPTER 1 INTRODUCTION The Staphylococci are a group of Gram-positive bacteria, 14 species are known to cause human infections but the vast majority of infections are caused by only three of them. They
More informationNorth West Neonatal Operational Delivery Network Working together to provide the highest standard of care for babies and families
Document Title and Reference : Guideline for the management of multi-drug resistant organisms (MDRO) Main Author (s) Simon Power Ratified by: GM NSG Date Ratified: February 2012 Review Date: March 2017
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationWHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health
New WHO report provides the most comprehensive picture of antibiotic resistance to date, with data from 114 countries 30 APRIL 2014 GENEVA - A new report by WHO its first to look at antimicrobial resistance,
More informationHealthcare-associated infections surveillance report
Healthcare-associated infections surveillance report Methicillin-resistant Staphylococcus aureus (MRSA) Update, Q3 of 2017/18 Summary Table Q3 2017/18 Previous quarter (Q2 2017/18) Same quarter of previous
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAn Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?
An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca
More informationA Conversation with Dr. Steve Solomon and Dr. Jean Patel on Antimicrobial Resistance June 18 th, 2013
A Conversation with Dr. Steve Solomon and Dr. Jean Patel on Antimicrobial Resistance June 18 th, 2013 Participant List Dr. Steve Solomon, Director, Office of Antimicrobial Resistance, Division of Healthcare
More informationBurden of disease of antibiotic resistance The example of MRSA. Eva Melander Clinical Microbiology, Lund University Hospital
Burden of disease of antibiotic resistance The example of MRSA Eva Melander Clinical Microbiology, Lund University Hospital Discovery of antibiotics Enormous medical gains Significantly reduced morbidity
More informationANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS
ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS PHM025D March 2016 Neha Maliwal Project Analyst ISBN: 1-62296-252-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More information